Usage Information
Citation Information: J Clin Invest. 1993;91(6):2523-2531. https://doi.org/10.1172/JCI116488.
Abstract
Follistatin is a glycoprotein, originally isolated from the gonads, that specifically inhibits follicle-stimulating hormone (FSH) biosynthesis and secretion. We have previously detected follistatin mRNA in rat pituitary gonadotropes. To assess the potential physiologic role of follistatin in the rat pituitary, we have investigated the effects of gonadectomy (GDX) and of sex steroid replacement on pituitary follistatin gene expression. Follistatin mRNA levels in individual rat pituitaries were measured by a quantitative reverse transcription-polymerase chain reaction assay. Female and male rats 21 d old underwent surgical GDX and were then killed 21 d after GDX. Follistatin mRNA levels in rat pituitary increased 3.2 +/- 1.5-fold (P < 0.01) in GDX female rats and 8.2 +/- 2.0-fold (P < 0.005) in GDX male rats, compared with intact female and male controls, respectively. Replacement therapy with 17 beta-estradiol-3-benzoate (10 micrograms/100 g body weight) subcutaneously daily for 7 d in GDX female rats resulted in a slight further increase in follistatin mRNA levels compared to GDX females. In contrast, therapy with testosterone propionate (500 micrograms/100 g body weight) subcutaneously daily for 7 d in GDX male rats resulted in a decrease in follistatin mRNA levels, towards but not completely back to baseline levels in intact males. Time-course studies in adult male and female rats showed that the increase in follistatin mRNA levels after GDX is rapid, with significant increases occurring within 24 h after GDX, and parallels or precedes increases in FSH beta mRNA levels and FSH secretion. The regulation of follistatin mRNA levels in the rat pituitary by GDX and by sex steroids suggests that follistatin may be important as an autocrine or paracrine factor in the regulation of FSH.
Authors
U B Kaiser, W W Chin
Usage data is cumulative from February 2024 through February 2025.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 129 | 3 |
| 55 | 22 | |
| Figure | 0 | 1 |
| Scanned page | 319 | 7 |
| Citation downloads | 54 | 0 |
| Totals | 557 | 33 |
| Total Views | 590 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)